The Importance of Scalability in Drug Manufacturing

Release date: June 6, 2023


  • Description

    In the rapidly evolving field of biotechnology, the successful development of innovative therapies requires scientific ingenuity and the capability to overcome numerous practical challenges. Among these, the scalability of the manufacturing process is a critical factor that can significantly impact the product’s viability from both quality and commercial perspectives. This example presents a case study of a Bay Area biotech company facing and overcoming manufacturing scale-up problems while developing a monoclonal antibody (mAb) for a neurological disorder. Names and select details have been intentionally omitted to safeguard the confidentiality of the parties involved.

    Regulatory agency:  EMA
    Stage of development:  Phase I

    The Challenge 

    The company’s promising mAb, in Phase I of development under the European Medicines Agency’s (EMA) oversight, encountered a significant obstacle. During the manufacturing scale-up, it was discovered that the process for creating the drug was not easily scalable. This issue led to inconsistent product quality and yield at larger manufacturing scales, posing severe potential consequences for the drug’s development and commercial viability.

    Potential impacts included varying levels of drug efficacy and safety due to inconsistent product quality, which could jeopardize clinical trials and ultimately delay regulatory approval. Additionally, a low yield could lead to a potential drug shortage, further delaying its market launch and undermining its commercial success.

    As part of the investigation, the company discovered that the titer values were much lower than initially observed at the research-scale production. Low titer values affect not only the yield but also the economics of the manufacturing process. Achieving a high titer is critical as it directly impacts the bioreactor volume required, affecting the overall production cost.

    The titer value in bioprocesses refers to the concentration of a product (often a monoclonal antibody or mAb) in the cell culture fluid. Achieving a high titer is critical in biopharmaceutical production as it directly impacts the process’s efficiency, economics, and scalability. Here’s a more in-depth exploration of the titer issue:

    Titer Issue in Detail

    In producing mAbs, achieving a high titer has always been a primary goal. Historically, mAb titers were very low, but cell line development, media formulation, and process optimization advancements have significantly improved titers. However, the challenge remains that as one scales up the production, maintaining or even approaching the desired titer can become a challenge due to various factors.

    • Cell Line Limitations: Not all cell lines have the same productivity. Some might have inherent limitations in their ability to produce high product quantities.
    • Nutrient Limitations: As cells grow and proliferate, they consume nutrients from the media. If not properly managed, these nutrients can become limiting, affecting cell health and productivity.
    • Process Inefficiencies: Parameters like pH, temperature, agitation speed, and oxygen levels can significantly impact cell productivity. Inconsistent or suboptimal process conditions can lead to low titer values.
    • Impurities or Contaminations: Impurities or microbial contamination can stress the cells, reducing productivity.

    Impact on drug development

    The scalability issue with the manufacturing process could negatively impact drug development, as noted. Firstly, inconsistent product quality could result in varying drug efficacy and safety levels, affecting clinical trials and delaying regulatory approval. Secondly, low yield could result in a drug shortage, further delaying its launch and impacting its commercial viability.

    • Inconsistent Product Quality: During the scale-up process, the company encountered challenges maintaining consistent product quality at larger production scales. As batch sizes increased, variations in product attributes emerged, leading to concerns about the drug’s effectiveness and safety. Analytical data indicated deviations in critical quality attributes (CQAs), such as purity, potency, and stability, which raised concerns about the reproducibility of the manufacturing process.
    • Yield Variability: Another significant issue during scale-up was the inconsistency in product yield. The initial manufacturing process demonstrated a satisfactory yield in smaller batches, but the yield decreased significantly as production scaled. This posed a substantial risk of potential drug shortages and hindered the company’s ability to meet future market demands.
    • Impact on Regulatory Approval: The EMA, as the regulatory agency overseeing the Phase I trial, closely monitored the manufacturing process’s progress. The scalability and product quality issues raised concerns about the therapy’s ability to meet regulatory standards for approval. Inconsistent product quality and yield could jeopardize the drug’s path to market approval, delaying its availability to patients in need.
    • Time and Cost Implications: Addressing scalability problems required extensive investigation, additional testing, and process modifications. This resulted in unexpected delays in the development timeline and increased manufacturing costs. As the company strived to resolve the issues, resources that could have been allocated to other critical aspects of drug development were diverted, impacting the project’s overall efficiency.

    Implications of Low Titer Values:

    • Economic Impact: Low titer values can have a profound economic impact. A higher titer means more product can be produced in the same culture volume, directly affecting the cost of goods. If the titer is too low, the process might not be commercially viable, especially for treatments for a large patient population.
    • Process Scalability: A process that works well at a small scale might not necessarily translate to a high titer at a larger scale. As the production volume increases, factors like oxygen transfer, nutrient distribution, and waste removal can become limiting, affecting cell health and productivity.
    • Resource Utilization: Low titer values mean more culture volume is required to produce the same amount of product. This can increase resource utilization, including larger bioreactors, more media, and downstream processing efforts.

    How the Issue was Resolved

    Addressing this challenge required a multi-faceted approach, combining an in-depth investigation, process optimization, quality control measures, additional clinical trials, and collaboration with experts in the field.

    The company first conducted a thorough investigation of the manufacturing process to identify the root cause of the scalability issue. The process was then optimized to improve product quality and yield at larger manufacturing scales. Rigorous quality control measures were implemented across all manufacturing scales to ensure consistency.

    The company undertook a comprehensive review of its cell lines, media, and feeding strategies in response to the low titer values. By optimizing the cell culture conditions and implementing a more consistent feeding regimen, they enhanced titer values, making the process more economical and efficient.

    Recognizing the importance of validating the safety and efficacy of the drug, the company implemented additional clinical trials for the product manufactured at larger scales. This step was crucial in maintaining confidence in the drug’s efficacy and safety profiles.

    Lastly, the company sought collaboration with experts in the field to identify innovative technologies or approaches that could further enhance the scalability of the manufacturing process. This proactive approach was critical to ensuring the drug’s timely launch and ultimately, commercial success.

    Addressing the Titer Challenge

    • Cell Line Development: Investing in robust cell line development strategies, like targeted gene amplification or metabolic engineering, can help create cell lines with higher productivity.
    • Process Optimization: Continuously monitoring and optimizing critical process parameters can help maintain an environment conducive to high productivity. Techniques like Design of Experiments (DoE) can be beneficial here.
    • Advanced Analytics and Feedback Control: Using real-time analytics to monitor nutrient levels, pH, dissolved oxygen, and other critical parameters and then adjusting them in real-time using feedback control systems can help maintain optimal conditions for high titer production.
    • Media and Feed Optimization: Developing specialized media and feed strategies tailored to the specific needs of the cell line can significantly boost titer values. This might involve adding certain supplements or adjusting the feeding schedule to ensure cells always have access to the necessary nutrients.

    The Role of Regulatory Agencies

    The EMA, as the regulatory agency overseeing the development, likely played an instrumental role in this process. It would have closely monitored the situation, requiring the company to provide regular updates on the issue and its resolution. Additional data and information would likely have been requested to assess the impact of the manufacturing scale-up problems on the drug’s safety, quality, and efficacy. In addition, the EMA may have conducted its inspections and audits of the manufacturing facilities to verify the company’s findings and ensure compliance with regulatory standards.

    It’s important to note that if the issues were not resolved to the satisfaction of the regulatory agency, the approval process for the drug could have been delayed or even suspended, potentially causing significant financial losses for the company. However, if the company demonstrated that they had taken appropriate steps to address the manufacturing scale-up problems and ensure the safety and efficacy of the drug, the EMA would have been more likely to approve the drug and allow it to proceed to the next development phase.

    Lessons Learned

    This case study underscores the importance of ensuring the scalability of the manufacturing process in drug development. It highlights how manufacturing scale-up problems can significantly impact product quality and yield, clinical trials, regulatory approval, and commercial viability.

    Moreover, it demonstrates the crucial role of regulatory agencies in the drug development process and the need for close monitoring and compliance with regulatory standards.

    Beyond the challenges presented here by low titer values, manufacturing and scale-up for biologics reinforce the necessity of:

    • Advanced Analytics: Utilizing advanced analytics can help identify issues such as inconsistent glycoform expression or aggregate formation early in the development process, allowing companies to intervene and rectify these issues before they become critical. Aggregation can adversely impact the drug’s stability, potency, and immunogenicity. It is a critical quality attribute that regulatory agencies, like the EMA, monitor closely. Aggregates can trigger immune responses in patients, leading to potential side effects and reduced drug efficacy.
    • Expert Collaboration: Collaborating with experts specializing in areas like glycosylation or protein aggregation can expedite the resolution of specific challenges. Their insights can provide tailored solutions that may not be immediately apparent to the broader team.
    • Flexibility in Process Design: Adopting a flexible approach to process design ensures that unexpected challenges, such as those outlined above, can be quickly addressed without significant disruptions to the overall development timeline.

    By emphasizing these additional lessons, organizations can further ensure the successful development and scale-up of innovative biologic therapies.

    The case study highlights the importance of early consideration of scalability during drug development. Critical lessons learned from this experience include:

    • Proactive Planning: Companies must consider scalability from the early stages of drug development. A rigorous evaluation of the manufacturing process’s feasibility and potential challenges can mitigate risks and ensure a smooth transition from clinical trials to commercial production.
    • Robust Process Characterization: Comprehensive process characterization, including risk assessments and identification of critical process parameters, is essential. Understanding how changes in scale may impact product quality and yield can guide decision-making and minimize surprises during scale-up.
    • Collaboration with Regulatory Experts: Engaging regulatory CMC strategy consultants, like Enkrisi, can provide invaluable insights into regulatory expectations and compliance requirements. Expert guidance can help streamline the approval process and reduce the risk of regulatory hurdles.
    • Continuous Process Improvement: Implementing a culture of continuous improvement allows companies to address challenges systematically. Ongoing data analysis and process optimization can enhance scalability and overall manufacturing efficiency.

    The critical takeaway is addressing scalability issues early in the drug development process. By doing so, companies can avoid potential delays and financial losses and pave the way for successful commercialization.

    In the end, this issue was successfully resolved due to the company’s proactive approach, commitment to quality, and willingness to collaborate with external experts. This experience is a valuable lesson for other biotech companies navigating the complexities of drug development and manufacturing scale-up. It’s a testament to the importance of problem-solving, adaptability, and continuous improvement in facing challenges. As the biotech industry evolves, such lessons will be critical for companies striving to bring innovative, safe, and effective therapies to market.

    By sharing this case study, we hope to provide insights and strategies to help other companies navigate similar challenges effectively. The journey from drug discovery to commercialization is filled with hurdles, and overcoming these obstacles requires both scientific prowess and operational excellence.

    The story of this Bay area biotech company serves as a reminder that, with the right approach, even significant manufacturing scale-up problems can be addressed and resolved, paving the way for potential therapeutic breakthroughs and commercial success.

Share this article:

See who else we’ve helped


The latest in biotech for your ears

The VirtualPharm Podcast is an audio series that covers topics related to compliance and regulatory affairs in the Lifesciences industry. Each episode, hosted by an expert in the topic with decades of experience, offers listeners detailed insight into the changing regulatory environment.

The latest in biotech for your eyes

The PathFinder focuses on relevant topics such as regulatory developments, compliance trends, legal updates, enforcement actions, industry insights, and best practices. Articles are written by experts in the field to ensure accuracy and help sponsor companies stay informed about changes in their regulatory environment.

Lets discuss your product